Welcome to our dedicated page for TELESCOPE INNOVATIONS news (Ticker: TELIF), a resource for investors and traders seeking the latest updates and insights on TELESCOPE INNOVATIONS stock.
Telescope Innovations Corp. (OTCQB: TELIF) regularly issues news and updates that highlight its progress in intelligent automation, Self-Driving Labs, and advanced chemical manufacturing technologies. Company announcements describe deployments of Self-Driving Labs for pharmaceutical research and education, development milestones in lithium processing technologies, and commercial traction for products such as DirectInject-LC™.
News releases detail Telescope’s installation of a pharmaceutical Self-Driving Lab for the Korean Pharmaceutical and Biopharmaceutical Manufacturers Association in Seoul, which the company describes as Korea’s first Self-Driving Lab for pharmaceutical development and training. Other updates cover a multi-year, funded Self-Driving Lab development project with Pfizer and broader initiatives to expand SDL adoption across pharmaceuticals, industrial chemistry, energy, and agriculture.
Telescope’s news flow also includes information on its proprietary lithium technologies, including the ReCRFT™ process for producing battery-grade lithium carbonate from battery recycling brines and the DualPure™ process for low-temperature lithium sulfide production. The company reports government funding approvals to advance and scale these processes, as well as participation in the Arkansas Lithium Technology Accelerator to explore commercialization pathways with industry partners.
In addition, Telescope publishes updates on corporate developments such as stock option and restricted share unit grants, debt settlement transactions using common shares, and executive appointments that support its growth in online analytics and Self-Driving Lab deployments. Investors and followers of TELIF can use this news stream to monitor operational milestones, technology validation, partnerships, and capital markets activity described directly by the company.
Telescope Innovations (OTCQB: TELIF) reported fiscal 2025 results for the year ended August 31, 2025, with revenues of CAD $5.8M versus $4.4M in FY2024 and an Adjusted EBITDA loss of $402K (FY2024 loss $152K). Expenses rose to CAD $7.3M.
Operational milestones include a multi‑year funded Self‑Driving Lab (SDL) project with Pfizer, record quarterly sales for DirectInject‑LC and expansion into Europe and Asia, production and first sample shipments of battery‑grade lithium sulfide, and planned deployment of the first SDL for pharmaceutical development in Korea in FY2026.
Telescope Innovations (OTCQB: TELIF) completed installation of Korea's first pharmaceutical Self-Driving Lab (SDL) for the Korean Pharmaceutical and Biopharmaceutical Manufacturers Association on December 9, 2025. The SDL was deployed only three weeks after contract signing, demonstrating rapid delivery capability. The project included on-site participation by two-time Chemistry Nobel Prize winner Prof. Barry Sharpless and was enabled by collaboration with the Acceleration Consortium and Canadian–Korean partners. Telescope says the installation will accelerate R&D workflows via automated robotics, inline analytics, and AI, and positions the company to expand SDL adoption across pharmaceutical, industrial chemistry, energy, and agricultural sectors.
Telescope Innovations (OTCQB: TELIF) announced that Korea's Pharmaceutical and Biopharmaceutical Manufacturers Association (KPBMA) has purchased a Self-Driving Lab (SDL) to be installed at a new R&D facility in Seoul within weeks (announcement dated November 17, 2025).
The SDL will form the core of KPBMA's first AI-driven training hub under the Convergence AI Institute for Drug Discovery (CAIID), supporting automation, education, and upskilling across KPBMA's 300 member companies. Telescope said the SDL uses robotics, inline analytics, and AI to run continuous closed-loop experiments that can accelerate iterative R&D and shorten development timelines. Telescope and KPBMA plan a strategic partnership to deploy and promote SDL adoption across Korea and the wider Asian market.
Telescope Innovations (OTCQB: TELIF) received formal and conditional government support totalling up to CAD $3.36M to advance lithium processing technologies on November 4, 2025. NRC IRAP provides advisory services and up to $319,200 for demonstration of ReCRFT™ lithium carbonate crystallization for battery recycling. NRCan CMRDD conditionally approved $3.04M to scale and pilot DualPure™ low-temperature lithium sulphide synthesis for solid-state battery materials. The programs run through Telescope's automated R&D labs to accelerate demonstration and scale-up.
Telescope Innovations (OTCQB: TELIF) announced a debt settlement on October 23, 2025, issuing a total of 689,654 common shares at a deemed price of CAD $0.29 per share.
The issuance settles CAD $100,000 of indebtedness to Jason Hein, CTO and director, via 344,827 shares, and CAD $100,000 of a secured loan via 344,827 shares. The secured loan originally provided CAD $1,200,000, bears 6.95% annual interest and matures on June 1, 2026.
Hein is a related party under MI 61-101; the company relied on exemptions to formal valuation and minority approval. All issued shares carry a statutory hold of four months and one day. Completion is subject to Canadian Securities Exchange and other regulatory approvals.
Telescope Innovations (OTCQB: TELIF) has achieved a significant breakthrough in battery recycling technology, successfully producing battery-grade lithium carbonate with >99.9% purity from recycled battery waste streams using their proprietary ReCRFT™ process.
Building on their April 2024 proof-of-concept, the company has demonstrated the ability to extract and refine lithium from complex battery waste materials. The process addresses a crucial challenge in battery recycling, as lithium represents 16% to 55% of the total metal value in spent batteries.
The company has partnered with Cellmine and the University of St Andrews for testing and validation of the recycled lithium carbonate in actual battery applications, marking an important step toward sustainable battery materials sourcing.
Telescope Innovations (OTCQB: TELIF), a leader in intelligent automation platforms for chemical process development, has appointed Vaso Vlachos as Chief Operating Officer. With over 20 years of experience in automation and analytical technology for biopharmaceutical and chemical industries, Vlachos joins from Mettler-Toledo AutoChem where she served as Global Head of Real-Time Analytics.
The company's DirectInject-LC product has doubled in sales opportunities in Q3 2025 compared to Q3 2024, with operations expanding from North America to Europe, Japan, and China. Telescope is also advancing Self-Driving Lab deployments with partners like Pfizer and developing lithium refinement technologies.
Additionally, the company granted 518,140 stock options to employees and consultants, exercisable at $0.43 until September 2, 2030.
Telescope Innovations (OTCQB: TELIF), a chemical process development automation company, has been selected to join ALTA (Arkansas Lithium Technology Accelerator), America's first lithium technology accelerator. The company will collaborate with industry leaders like Standard Lithium, Albemarle, ExxonMobil, and Chevron.
Telescope brings two key technologies to ALTA: ReCRFT™, a low-capital method for producing battery-grade lithium carbonate, and DualPure™, a process for creating lithium sulfide for solid-state batteries. ReCRFT™ has been validated with feedstocks from over 8 North American sites, while DualPure™ samples are being evaluated by battery industry groups in North America and Asia.
This strategic engagement comes as Telescope prepares for pilot-scale deployment of its technologies, with ALTA providing direct access to leading lithium producers for technical collaboration and operational validation.
Telescope Innovations (OTCQB:TELIF), a developer of advanced technologies for pharmaceutical and chemical industries, reported its Q3 2025 financial results. The company achieved revenues of CAD $1.39 million, up from CAD $1.22 million in Q3 2024, with an adjusted EBITA loss of CAD $99,466.
The quarter saw strong performance of their DirectInject-LC™ product, with doubled opportunities compared to Q3 2024 and successful expansion into Asian markets. Telescope is finalizing a Phase 1 Self-Driving Lab platform with Pfizer and has shipped its first battery-grade lithium sulfide samples to major battery industry groups, leveraging its proprietary low-temperature production process.
The company maintains strategic partnerships with Mettler Toledo, Pfizer, and Standard Lithium, positioning itself for continued growth in analytical and automation innovations.